|
Treatment Regimens for Drug Resistant Tuberculosis: A Retrospective Observational Study
|
|
| Author:
|
SULTANA G, MOHAMMED MUSA SAADUDDIN, SAI NIHARIKA BN, MANASA A, TARANUM SULTANA AB, DHANALAKSHMI D
|
| Abstract:
|
Background and objective: India has one of the highest burdens of drug-resistant tuberculosis worldwide.
The drug-resistant tuberculosis (DR-TB) also has become an alarming issue in recent time due to its constant
spread throughout the world. Current regimens for drug-resistant tuberculosis are complicated, lengthy, and
expensive compared to those used to treat drug-susceptible tuberculosis, leaving patients with much less
effective treatment options. The objective of the study was to evaluate different regimens for drug-resistant
tuberculosis in a tertiary care hospital from January 2015 to December 2019.
Methodology: A retrospective observational study was conducted at Government General and Chest
Hospital, Hyderabad, India. Patients with bacteriologically confirmed tuberculosis with evidence of resistance
to Rifampicin and/or Isoniazid and Fluoroquinolones and/or Injectables and having an age above 18 years were
included in the study.
Results: 373 patients were included in the study and analyzed. Most of the patients were diagnosed with
Multi-drug resistant tuberculosis (91.95%) and the most commonly prescribed regimen was a Shorter multidrug resistant tuberculosis regimen (49.33%) followed by a longer multi-drug resistant tuberculosis regimen
(42.63%), Bedaquiline regimen for extended drug-resistant tuberculosis(6.17%) and Regimen for Isoniazid
Monoresistant tuberculosis (1.07%). The Shorter regimen was found to be successful in 33.15% whereas longer
regimen was successful in 26.41% of patients. Around 23.32% of the patients experienced 122 adverse drug
events. Gastrointestinal adverse events were found to be more common.
Conclusion: The Shorter regimen was found to be slightly more successful when compared to longer
regimens for the treatment of Multi-drug resistant tuberculosis, but was associated with a higher frequency of
adverse drug events.
|
| Keyword:
|
anti-tubercular drugs, treatment regimens, treatment outcomes, adverse drug events.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2022.14.04.004
|
| Download:
|
Request For Article
|
|
|